GenPharm International Inc., which is developing human proteins fromtransgenic animals, said it raised $3 million in new equity financingfrom Japanese investors."This is the first leg of an Asian investment round," JonathanMacQuitty, president of the privately held company, told BioWorld."In the next round we will have investors from other Asian countries,together possibly with some U.S. investors."The Mountain View, Calif., company has a transgenic bull namedHerman, who was microinjected with a gene for human lactoferrin.Heifers then were artificially inseminated with semen from Herman,and produced 23 transgenic calves. MacQuitty said initial lactation datafrom the second generation of calves will be available by the end of theyear.GenPharm has a collaboration with Eisai Co. Ltd. of Tokyo, which haslicensed Asian marketing rights to a human monoclonal antibody foran unnamed antigen. MacQuitty said this financing round will facilitatecollaborations with other Japanese companies, both in the antibodyprogram and in the human protein area. _ Jim Shrine

(c) 1997 American Health Consultants. All rights reserved.

No Comments